205 related articles for article (PubMed ID: 30427124)
21. Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study.
Shuey MM; Gandelman JS; Chung CP; Nian H; Yu C; Denny JC; Brown NJ
BMJ Open; 2018 Jun; 8(6):e021640. PubMed ID: 29950471
[TBL] [Abstract][Full Text] [Related]
22. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
[TBL] [Abstract][Full Text] [Related]
23. Acute kidney injury is a risk factor for subsequent proteinuria.
Parr SK; Matheny ME; Abdel-Kader K; Greevy RA; Bian A; Fly J; Chen G; Speroff T; Hung AM; Ikizler TA; Siew ED
Kidney Int; 2018 Feb; 93(2):460-469. PubMed ID: 28927644
[TBL] [Abstract][Full Text] [Related]
24. Potentially Inappropriate Antihypertensive Prescriptions to Elderly Patients: Results of a Prospective, Observational Study.
Márquez PHP; Torres OH; San-José A; Vidal X; Agustí A; Formiga F; López-Soto A; Ramírez-Duque N; Fernández-Moyano A; Garcia-Moreno J; Arroyo JA; Ruiz D;
Drugs Aging; 2017 Jun; 34(6):453-466. PubMed ID: 28432600
[TBL] [Abstract][Full Text] [Related]
25. Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study.
McCoy IE; Han J; Montez-Rath ME; Chertow GM
Mayo Clin Proc; 2021 Aug; 96(8):2114-2122. PubMed ID: 33952396
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive drug treatment changes in the general population: the CoLaus study.
Christe V; Waeber G; Vollenweider P; Marques-Vidal P
BMC Pharmacol Toxicol; 2014 Mar; 15():20. PubMed ID: 24685255
[TBL] [Abstract][Full Text] [Related]
27. Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report.
Colvin CL; King JB; Oparil S; Wright JT; Ogedegbe G; Mohanty A; Hardy ST; Huang L; Hess R; Muntner P; Bress A
JAMA Netw Open; 2020 Nov; 3(11):e2025127. PubMed ID: 33206191
[TBL] [Abstract][Full Text] [Related]
28. Prescription pattern of antihypertensive medications and blood pressure control among hypertensive outpatients at the University of Benin Teaching Hospital in Benin City, Nigeria.
Adejumo O; Okaka E; Iyawe I
Malawi Med J; 2017 Jun; 29(2):113-117. PubMed ID: 28955417
[TBL] [Abstract][Full Text] [Related]
29. Patterns of antihypertensive therapy among patients with diabetes.
Johnson ML; Singh H
J Gen Intern Med; 2005 Sep; 20(9):842-6. PubMed ID: 16117753
[TBL] [Abstract][Full Text] [Related]
30. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
31. Medical treatment of hypertension in Switzerland. The 2009 Swiss Hypertension Survey (SWISSHYPE).
Brenner R; Waeber B; Allemann Y
Swiss Med Wkly; 2011; 141():w13169. PubMed ID: 21374529
[TBL] [Abstract][Full Text] [Related]
32. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
Yanagi M; Tamura K; Fujikawa T; Wakui H; Kanaoka T; Ohsawa M; Azushima K; Maeda A; Kobori H; Umemura S
Hypertens Res; 2013 Mar; 36(3):262-9. PubMed ID: 23154587
[TBL] [Abstract][Full Text] [Related]
33. Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease.
Uneda K; Tamura K; Wakui H; Azushima K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Ohsawa M; Fujikawa T; Umemura S
Clin Exp Hypertens; 2016; 38(8):738-743. PubMed ID: 27936941
[TBL] [Abstract][Full Text] [Related]
34. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
35. Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network.
Smith SM; Winterstein AG; Gurka MJ; Walsh MG; Keshwani S; Libby AM; Hogan WR; Pepine CJ; Cooper-DeHoff RM
J Am Heart Assoc; 2023 Jan; 12(1):e026652. PubMed ID: 36565195
[TBL] [Abstract][Full Text] [Related]
36. The Number of Pills, Rather Than the Type of Renin-Angiotensin System Inhibitor, Predicts Ambulatory Blood Pressure Control in Essential Hypertensives on Triple Therapy: A Real-Life Cross-Sectional Study.
Sarzani R; Giulietti F; Filipponi A; Marziali S; Ristori L; Buscarini S; Garbuglia C; Biondini S; Allevi M; Spannella F
Adv Ther; 2021 Jul; 38(7):4013-4025. PubMed ID: 34115328
[TBL] [Abstract][Full Text] [Related]
37. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
[TBL] [Abstract][Full Text] [Related]
38. [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
Chazova IE; Martynyuk TV
Ter Arkh; 2013; 85(9):35-45. PubMed ID: 24261228
[TBL] [Abstract][Full Text] [Related]
39. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
40. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
